Israeli firm Teva buying Auspex for $3.2 billion
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.
Jerusalem-based Teva said Monday that it will pay $101 per share, marking a 47 percent premium to San Diego-based Auspex's closing stock price on Friday.
Auspex does not yet have a product on the market. Its lead product candidate is Austedo, which is aimed at treating involuntary movement associated with the genetic disorder Huntington's disease.
Glenn Drew: Our students attend Harvard and Princeton on quite a regular basis
Interview with CEO of the American Hebrew Academy
Igor Kolomoisky: I told Yatsenyuk he was putting himself at risk
On relations with the president, his administration and Prime Minister Arseny Yatsenyuk
New High-Tech Collar Tracks The Health Of Your Pets
The PetPace collar uses non-invasive sensors to monitor data